CeriBell (NASDAQ:CBLL) Sets New 52-Week Low – What’s Next?

CeriBell (NASDAQ:CBLL)’s share price reached a new 52-week low during trading on Tuesday . The company traded as low as $18.50 and last traded at $18.75, with a volume of 12642 shares traded. The stock had previously closed at $19.21.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CBLL. TD Cowen increased their price objective on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group restated a “buy” rating and issued a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $32.60.

CeriBell Stock Up 2.5 %

The firm’s 50-day moving average price is $22.13.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts’ expectations of $17.55 million. As a group, equities analysts expect that CeriBell will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new stake in CeriBell in the fourth quarter valued at approximately $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell during the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC bought a new stake in shares of CeriBell in the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets bought a new stake in CeriBell in the fourth quarter valued at $43,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of CeriBell during the 4th quarter valued at about $47,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.